Abd El Aziz M et al
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, researchers compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Long-term use of Ozempic should be re-evaluated periodically by a healthcare provider to confirm ongoing benefit
The organization has 619 employees including actors and technicians
The discrepancy in the reports of p53 expression in keloids 5,26,27 suggests that the regulatory functions of p53 in keloid fibroblasts depends on activities rather than expression levels of p53
Question Does less receptor overlap mean lower risk